Bal Pharma Revises Preferential Warrant Issue to ₹84
Fundraising / Financing
Price while announcement
Current price (CMP)
Tulsian AI News Agent
·
23rd Jul 2026
Key Revisions to Preferential Issue
Revised Issue Price
- Warrant issue price increased from ₹81 to ₹84 per warrant
- Premium component: ₹74 per warrant
- Total consideration revised from ₹8.10 crore to ₹8.40 crore for 10,00,000 warrants
- Each warrant convertible into 1 equity share of face value ₹10
Pricing Methodology
- NSE considered for floor price determination due to higher trading volumes
- Valuation report dated July 22, 2026 from CA S. Bhaskar (IBBI/RV/06/2019/12116)
- Valuation approaches: Market Approach (₹83.869), Income & Cost Approach (₹82.65), Asset Approach (₹45.76)
- Minimum price determined as ₹83.869 per warrant based on highest valuation approach
- Final issue price of ₹84 exceeds regulatory minimum requirement
Revised Payment Terms
- 25% payment (₹21 per warrant) required on allotment date
- Balance 75% (₹63 per warrant) payable before conversion into equity shares
- Conversion period: 18 months from allotment date
- Full forfeiture of paid amount if not converted within 18 months
Objects of the Issue
- Funding Greenfield API Manufacturing Facility at Yadgiri, Karnataka
- Project cost: Approximately ₹300 crores
- Land already acquired: 5 acres at Plot No. 540/20, Kadechur & Badiyal Industrial Area
- Land premium: ₹236.5 lakhs (₹47.30 lakhs/acre)
- Building cost: Approximately ₹11 crores
- Environmental Clearance obtained from MoEF&CC (EC Identification No: EC25B2405KA5738522N)
- Project currently at implementation stage
Utilization of Proceeds
- 100% of issue proceeds (₹8.40 crore) allocated to API facility project
- Tentative utilization timeline: By December 31, 2027
- Interim deployment permitted with scheduled commercial banks
- Funds received in tranches based on warrant conversion schedule
Shareholding Impact
Post-Issue Fully Diluted Shareholding Pattern (assuming 100% conversion):
- Total shares: 1,79,20,872 (from 1,59,20,872 pre-issue)
- Promoter holding: 90,97,182 shares (50.76% from 50.86%)
- Indian promoters: 84,41,995 shares (47.11% from 46.74%)
- Foreign promoters: 6,55,187 shares (3.66% from 4.12%)
- Public holding: 88,23,690 shares (49.24% from 49.14%)
Proposed Allottee Holding:
- Mr. Shailesh Siroya (Promoter)
- Pre-issue: 27,45,459 shares (17.24%)
- Post-issue: 37,45,459 shares (20.89% on fully diluted basis)
- No change in promoter status or company control
Voting Process
- Remote e-Voting period: July 10, 2026 (9:00 AM) to August 8, 2026 (5:00 PM)
- Members who voted before corrigendum can modify votes by email to scrutinizer (parameshwar@vjkt.in) with copy to evoting@nsdl.com
- Modification deadline: August 8, 2026, 5:00 PM
- Scrutinizer to ensure modified votes are considered in final tally
Additional Information
- Corrigendum forms integral part of original Postal Ballot Notice
- All unchanged terms from original notice remain valid
- Documents available on company website: www.balpharma.com
- Compliance officer: Shreepada ML, Company Secretary (ICSI M No: A66681)